Rasna Therapeutics, Inc. reported earnings results for the full year ended September 30, 2021. For the full year, the company reported net loss was USD 0.785082 million compared to USD 5.35 million a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.08 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0125 USD | -27.75% | 0.00% | +62.34% |
1st Jan change | Capi. | |
---|---|---|
+62.34% | 13.35M | |
+2.97% | 108B | |
+10.21% | 105B | |
+1.57% | 23.46B | |
-12.77% | 21.72B | |
-7.05% | 18.64B | |
-37.64% | 17.45B | |
-6.50% | 17.19B | |
+6.00% | 13.99B | |
+37.20% | 12.53B |
- Stock Market
- Equities
- RASP Stock
- News Actavia Life Sciences, Inc.
- Rasna Therapeutics, Inc. Reports Earnings Results for the Full Year Ended September 30, 2021